RESEARCH DOSSIER
Health Insurance Claims Appeals and Independent Review
Abstract. Health insurance appeals and independent review govern how contested benefits are reconsidered, independently adjudicated, and converted into effective relief. This fundamental research monograph examines the legal and economic character of adverse benefit determinations, identifies denial reasons across clinical and administrative stages, and compares review architectures in U.S. ACA-regulated insurance, employer plans, Medicare Advantage, Medicaid managed care, the United Kingdom, European supervisory practice, Australia, and the Netherlands. It synthesizes primary regulations, regulatory guidance, administrative reporting, government audits, national surveys, and peer-reviewed studies. KFF's analysis of 2024 HealthCare.gov qualified health plan data records an approximately 19 percent in-network claim denial rate, fewer than one percent formally appealed, and approximately two-thirds of decided internal appeals upheld, while a selected four-state study of independent medical review finds nearly half of reviewed denials overturned. Their different populations and denominators preclude a common error-rate interpretation. The monograph reconstructs clinical, contractual, coding, and eligibility disputes; assesses independence, evidence access, procedural timing, and binding effect; and develops explicit measurement definitions and hypothetical calculations without creating a new theory. Its original synthesis shows that substantive accuracy, accessibility of contest, and realized remediation must be measured jointly. Limits include selected jurisdictions, uneven administrative disclosure, unexamined private case files, and selective access to scholarly full texts.
Keywords: Health insurance; adverse benefit determination; claim denial; internal appeal; external review; independent medical review; medical necessity; benefit exclusion; coding denial; prior authorization; Medicare Advantage; Medicaid managed care; ERISA; Affordable Care Act; financial ombudsman; complaints handling; administrative burden; equity; access to care; appeals statistics; legal remedies; cross-jurisdictional analysis.
Introduction: Research Object, Questions, and Method
The health insurance claim is an operational assertion that a health plan owes authorization, payment, reimbursement, continued benefits, or another contractually or legally specified response. An appeal is a request to reconsider an adverse benefit determination through a procedure established by applicable law, contract, or program regulation. Independent review places an eligible controversy before a decision maker outside the original insurer's adjudicatory hierarchy. These stages form an essential part of the institutional infrastructure of insurance: the legal promise of coverage acquires practical meaning through access to evidence, a reasoned decision, a timely remedy, and a mechanism to correct error.
The principal scientific problem is to explain how the grounds for denying health insurance benefits interact with the standards of reconsideration and the real-world ability of patients to obtain a timely, fair result. This monograph investigates three approved axes: claim denial grounds; review standards and remedies; and timeliness and fairness outcomes. It is grounded in the published IAIS Insurance Core Principles, the U.S. federal appeals regulation, program-specific sources, international complaints procedures, and original observational research. Its central unit of analysis changes with the question. Claim-level denial ratios describe adjudicated transactions; person-level surveys describe patient experience; review cases describe selected appeals; and regulatory requirements apply to particular plans, jurisdictions, and periods.
The research questions are whether different denial reasons invite different standards of review; whether an independent reviewer can correct clinical, administrative, and contractual decisions with equal authority; how substantive entitlements and procedural protections interact; and how selection into appeals changes the interpretation of observed reversal rates. The study also asks what comparative institutions reveal about independent dispute resolution, legal remedies, accessibility, and the statistical evaluation of fairness.
Methodology combines source-critical reading of regulatory texts and official guidance; institutional process reconstruction; a structured comparison of the United States, United Kingdom, European supervisory rules, Australia, and the Netherlands; appraisal of administrative reporting and peer-reviewed studies; and transparent descriptive and counterfactual illustrations. Documentary statements are distinguished from observations, formal identities, and hypotheses. The monograph does not undertake an original claims-file audit, randomized intervention, systematic meta-analysis, comprehensive national legal survey, or personalized determination of eligibility. The cut-off for source review is November 16, 2026. Legal provisions are reported for the schemes and dates described by the cited sources.
The distinction between the decision, its contest, and eventual access to care governs the analysis. A claim may be finally paid after resubmission without formally entering an appeal. A favorable review may occur after care has become clinically less valuable. A statistical reversal may represent new evidence, corrected coding, a change in coverage interpretation, or a judgment that the original decision was mistaken. The event history must be retained before any reliable inference about effectiveness is drawn.
Foundations and Source-Critical History
Coverage promises, administrative decisions, and review institutions
Health insurance organizes contingent financial and service rights through a combination of coverage rules, clinical evidence standards, provider networks, utilization controls, cost-sharing schedules, and payment arrangements. A benefit claim may be initiated by a patient, an authorized representative, or a provider, but the legal holder of review rights depends on the product and program. Adverse outcomes encompass a refusal to authorize a requested intervention, a denial of payment after delivery, a reduction or termination of ongoing care, an unfavorable formulary or medical-necessity determination, and rescission in schemes where that is appealable. The ACA internal review regulation defines adverse benefit determinations more precisely for its own scope and supplies procedural safeguards. It cannot be treated as a universal definition for all public and private health financing arrangements.
Claims handling is historically associated with verification of insured events and contractual indemnity. Modern medical insurance introduced distinctive difficulties because medical need, clinical effectiveness, reimbursement coding, provider negotiation, and timing can all be disputed while treatment decisions remain urgent. The internal appeal creates an opportunity for correction by the institution that issued the initial denial. External review changes the institutional location of a judgment; it may depend on expert clinical reviewers, an ombudsman, a tribunal, or a statutorily independent contractor. In private medical insurance complaints, the United Kingdom's Financial Ombudsman Service considers policy terms, regulation, and fair treatment. In the Dutch SKGZ dispute process, mediation may be followed by a disputes board with binding advice. These different structures share a concern for contestability while varying in legal foundation and available remedies.
Evidence hierarchy and legal scope
Primary law controls the legal meaning of a remedy in its jurisdiction. Regulations specify decision deadlines, reviewable denials, notice obligations, representation, and hearing entitlements. Supervisory standards guide governance, and ombudsman decisions apply the relevant legal framework to disputes. Secondary analyses of official data illuminate frequency and patterns but cannot create legal rights. Scholarly observational studies contribute accounts of burden, selection, and unequal outcomes without making their samples representative of all insurance systems.
The IAIS supervisory conduct standards address timely, fair, and transparent insurance practices. The EIOPA complaints-handling guidelines specify internal complaint management expectations for insurers in the European regulatory environment. They form valuable comparative benchmarks, but a guideline's supervisory role must be separated from the direct enforceability of a national contract or administrative decision. A U.S. Medicare Advantage reconsideration, a Medicaid fair hearing, and an ACA market external review likewise proceed under different federal authorities; a description of one cannot simply replace the others.
What counts as an appeal?
The terms grievance, reconsideration, review, external appeal, independent medical review, fair hearing, and complaint overlap in ordinary discourse while carrying distinct procedural meanings. An appeal generally challenges an adverse benefit determination. A grievance may concern service quality or administrative behavior without an adverse benefit determination. A provider billing correction may resolve a claim before an appeal is lodged. An insurer's internal reconsideration may include a clinician or different personnel but still be internal. A legally independent external review demands an appropriate institutional separation as well as authority to reach the relevant question.
Under the Medicaid managed-care appeal rule, an enrollee is generally entitled to one plan-level appeal before proceeding to a state fair hearing after an upheld decision, while a state may offer an optional independent medical review under conditions that preserve hearing rights. A different sequence applies to Medicare Advantage: the Part C independent review procedure automatically receives unfavorable plan reconsiderations. These distinctions show why longitudinal data must record every stage and the applicable legal route.
Comparative research design
The comparison evaluates six institutional questions: who can challenge the decision; which denials are reviewable; who controls the evidence; how review independence is secured; what timing rules apply; and which remedies are actually available. Eligibility is studied through the governing insurance arrangement rather than assumed from the word “health insurance.” Causal inference requires additional information about selection into coverage, review, and eventual treatment. The comparative design therefore reports institutional differences and carefully bounded empirical findings rather than inferring national performance rankings from incompatible official counts.
Claim Denial Grounds and the Structure of Contestation
Contractual exclusion, enrollment, and benefit definition
The first group of denial grounds concerns the boundary of an insured entitlement. Services may be excluded, outside an effective coverage period, subject to specified waiting conditions, or limited by plan documents or legal benefits rules. A denial may also arise from a disagreement about whether the claimant was eligible, the requested provider was within network, or a prior authorization requirement applied. Contract terms must be interpreted under the law and program rules governing the plan. In UK medical insurance disputes, the ombudsman explicitly examines policy wording alongside applicable regulatory and fair-practice considerations.
An analytically important distinction exists between exclusion and evidentiary insufficiency. A service outside the benefit package will not become covered merely by supplying another clinical note. A service that is covered when medically necessary may require more evidence or a correction to the clinical record. A coding error may disappear after proper resubmission. Therefore, the nominal reason on a denial notice must be connected to the actual rule applied, the record reviewed, and the feasible means of contest.
Medical necessity and clinical judgment
Medical necessity denials engage questions about diagnosis, expected benefit, therapeutic alternatives, accepted clinical standards, and the policy's definition of covered treatment. The appropriate reviewer must be competent to evaluate these issues, and the claimant should be able to see the criteria used. The federal appeals process regulation provides rights to relevant claim-file materials and specifies independent and impartial adjudication within its scope; external review under the applicable federal process evaluates clinical circumstances and may proceed de novo.
The HHS Office of Inspector General's Medicare Advantage denial evaluation offers a particularly useful source-critical example. In a review of samples of denied prior-authorization and payment requests, some denials satisfied the relevant Medicare rules. The report estimated that 13 percent of the reviewed denied prior-authorization requests met Medicare coverage rules, and a separate 18 percent of reviewed payment denials met Medicare coverage and billing rules. These sample-based findings concern the cases and period investigated; they do not establish that 13 or 18 percent of every insurer's decisions are erroneous. The inspectors identified use of internal clinical criteria, documentation demands, and review or system errors as possible mechanisms. This evidence demonstrates the necessity of auditing actual decision criteria against authoritative benefit standards.
Experimental, investigational, and emerging treatments
Disputes about new diagnostics and therapeutics often turn on evidence quality, indications, the policy's definition of experimental or investigational care, and the relationship between clinical innovation and established coverage criteria. Novelty by itself neither settles coverage nor proves clinical benefit. A defensible review record must identify which evidence was available when the decision was made, how the plan defined the technology, whether a statutory rule displaces particular exclusions, and what alternatives were considered.
In federal external review guidance, denials involving medical judgment or experimental and investigational treatment are among the categories generally described as eligible for external review under the applicable framework. This makes independent review especially consequential when the central dispute concerns interpretation of clinical evidence. Yet the scope of an external reviewer is not infinitely broad: a reviewer may interpret coverage standards and clinical questions while remaining constrained by explicit legal exclusions, program benefits, and permissible review issues.
Administrative, coding, and coordination denials
Administrative denials may reflect missing information, claim submission windows, provider identifiers, invalid codes, duplicate claims, billing rules, prior authorization failures, eligibility records, and coordination between payers. The distinction between a final denial and an interim payment-processing rejection matters. A corrected claim can be resubmitted and paid, removing it from the final denied-claim population in some datasets. The KFF 2024 claims analysis explicitly notes this feature of the CMS transparency series. A machine-readable denial code without the applicable policy clause or explanatory text may be insufficient for substantive review.
These categories also have different economic implications. A short-lived coding error can create administrative work without materially impairing clinical access. An authorization denial before a time-sensitive intervention can impose a health risk before any reimbursement dispute begins. A payment denial after completed treatment can transfer immediate collection risk to a patient or provider. A reasonable assessment therefore identifies timing, service stage, and financial exposure in addition to the denial label.
Financial incentives and review quality
Private and publicly contracted insurance organizations operate under budget constraints, payment incentives, network contracts, and regulatory performance obligations. Denying a covered service may reduce immediate spending but increase appeal costs, correction rates, regulatory intervention, patient harm, and reputational loss. Paying an ineligible claim may increase expenditure and weaken consistent benefit administration. The relevant goal for adjudication quality is a reasoned determination of entitlement under the applicable rules.
The existence of cost-control incentives cannot by itself identify why a particular claim was denied. Evidence must connect the decision to criteria, personnel, documentation, oversight, or statistically detectable patterns. The OIG findings demonstrate how selected files can be examined against a benchmark; they do not prove intent in individual cases. For research, intent, procedural failure, erroneous adjudication, and lawful exclusion are separate propositions and require different kinds of evidence.
Formal distinction between denials, reversals, and corrections
Let N denote completed claims in a specified cohort, D the claims finally recorded as denied, A the denied claims formally appealed, and R the appealed claims reversed. The denial fraction D/N, the appeal rate A/D, and the reversal rate R/A have different denominators and answer different questions. Under consistent definitions, R/D=(A/D)(R/A). This identity is a bookkeeping relation, not a causal account of appeal effectiveness. The cohort must also be defined by network status, service date, filing date, product, jurisdiction, claim type, and whether payment resubmissions were included.
The algebra shows why a high reversal rate among selected appeals can coexist with a tiny share of total denials being reversed through formal appeal. It also shows why the average upheld rate cannot establish accuracy without knowing which denials entered the appeal process and what information became available. The distinction becomes foundational in assessing fairness and outcomes.
Review Standards, Independence, and Remedies
Internal appeals: notice, evidence, and full review
An effective internal appeal procedure must provide an intelligible route from denial to reconsideration. The claimant needs a comprehensible account of the denied item or service, the governing benefit rule, the clinical or administrative justification, the filing deadline, and the supporting evidence. The DOL health benefits guide explains for covered employer plans that claimants generally receive at least 180 days to request internal review and can obtain relevant records without charge. It also describes review by an individual distinct from the initial adjudicator, with medical expertise when medical judgment is involved. The HealthCare.gov internal appeals guide similarly identifies the need to retain denial letters, claim numbers, clinicians' letters, and communications records.
Procedural fairness has informational and institutional dimensions. Access to records permits an applicant to rebut factual assertions. A different reviewer reduces the risk that an adjudicator simply ratifies an earlier decision. Clear reasons allow an external reviewer to locate the disagreement. These safeguards improve the possibility of correction, but their effect depends on communication, accessibility, and practical capacity to engage.
Expedited clinical review and time-sensitive rights
A denial that occurs before surgery or during ongoing treatment creates a different risk profile from a disputed charge after care. Where the relevant federal employee-plan rules apply, the EBSA claims guidance distinguishes urgent, pre-service, and post-service appeals, with ordinarily 72 hours, 30 days, and 60 days as their respective maximum internal decision frames, subject to important plan-specific procedural details. The ACA review regulation establishes further protections for covered nongrandfathered plans and makes certain urgent external reviews available before ordinary exhaustion would be safe.
“Expedited” must have operational meaning. A procedure that reaches a decision within a formal deadline can still be inadequate for a rapidly deteriorating patient if the underlying rule requires response as quickly as medical exigencies demand. Relevant measures include elapsed time from clinical request to a final actionable authorization, the availability of interim treatment, and whether authorized care was delivered. Formal processing time alone cannot capture the consequences of a missed clinical window.
External review: independence and jurisdiction
Independent review assigns the eligible dispute to a body outside the plan's original decision chain. Independence requires attention to reviewer appointment, conflicts of interest, compensation, access to records, subject-matter competence, and the authority to issue a binding outcome when the governing process provides one. The federal external review standard includes provisions concerning independent review organizations and requires compliance with the applicable state or federal route. Its federal process can require the plan to implement a reversal promptly. The HHS federal external review process details a designated administrator for a category of federally administered external review cases; this is one route among several, not the universal procedure for all U.S. health coverage.
Independent and internal procedures are connected but conceptually distinct. If the external body assesses whether a clinical service meets a covered standard, it can overturn the insurer's medical judgment. If an unresolved question belongs to the courts or an administrative hearing, the independent review decision may not exhaust all legal channels. Independence thus describes the decision-making relationship; jurisdiction determines what can actually be decided.
Medicaid managed care and state fair hearings
Medicaid managed care has a program-specific structure. The Medicaid grievance and appeal rule provides one level of managed-care appeal and a 60-calendar-day window to appeal an adverse benefit determination. The Medicaid resolution and hearing rule specifies that states set standard appeal response periods of no more than 30 calendar days and expedited periods of no more than 72 hours, with strictly defined potential extensions. On an upheld determination, the notice must explain the state fair-hearing right; a compliant optional independent medical review must not delay or deter that hearing.
These procedural details change the definition of “external” oversight. A fair hearing is a formal administrative adjudicative process linked to a public benefit program. An optional independent medical review may supply specialist clinical evaluation without substituting for the hearing. Analyses that label all Medicaid escalations “external appeals” would conceal the separate rights, deadlines, and evidentiary functions established in federal regulation.
Medicare Advantage and independent reconsideration
Medicare Advantage provides another distinct pathway. Under CMS Part C plan reconsideration guidance, a plan beneficiary or authorized party generally has 65 calendar days from the adverse determination notice to seek reconsideration. The plan's decision periods vary by urgency, prospective service, Part B drug, and payment request. An unfavorable reconsideration is automatically transmitted to the Part C Independent Review Entity, rather than depending only on a patient initiating a separate external filing. CMS's Part C IRE instructions describe further access to adjudication after the independent review.
This structural difference can increase the number of reviews recorded relative to a voluntary external-review design, even without a difference in initial denial quality. Furthermore, the 2026 managed-care guidance update records a July 6, 2026 revision and a Part C IRE contractor transition on May 1, 2026, from MAXIMUS to C2C Innovative Solutions for newly received cases. Historical performance series must therefore keep the exact calendar period, contractor, and process version attached to the reviewed cases.
United Kingdom: conduct and ombudsman review
The FCA claims-handling rulebook requires insurers within ICOBS 8's scope to handle claims promptly and fairly, assist claimants, avoid unreasonable rejection, and settle promptly after agreement. The Financial Ombudsman medical claims guidance describes an independent process assessing the relevant policy, law, regulatory standards, and fair practice. For most private medical insurance complaints, the policyholder first raises the matter with the financial business. The ombudsman referral time limits describe the usual eight-week business-response threshold and six-month period following a valid final response, subject to exceptions.
The British route has a different institutional character from the U.S. clinician-focused statutory external review: it can assess claims conduct and the fairness of financial business practices alongside policy terms. In the present comparative analysis, the United Kingdom represents an integrated financial-ombudsman approach, not an all-purpose appeals process for public National Health Service treatment decisions.
European supervision, Australia, and the Netherlands
The EIOPA complaints-handling guidelines address internal complaint governance and information for insurance undertakings in the European supervisory environment. These guidelines support the organizational expectation that complaints be registered, investigated, reported, and monitored; national law supplies the specific forum and enforceable remedy. The Australian private health insurance ombudsman offers an independent avenue for complaints concerning health fund benefits, policy restrictions, membership, advice, and associated service problems. This scope illustrates how a health insurance complaint mechanism can extend beyond clinical necessity decisions.
The Netherlands SKGZ complaint procedure generally begins with a request that the insurer reconsider, allows free ombudsman mediation after an upheld decision or non-response in the specified period, and permits referral to a disputes board that issues binding advice. The official English guidance indicates a fee for the latter process and discusses potential court enforcement. Because the legal character, accessibility, and enforcement of these routes differ, a comparison should report whether “independent review” means clinical judgment, ombudsman recommendation, binding contractual dispute resolution, or an administrative hearing.
Remedies after a successful challenge
A favorable determination may require coverage authorization, reimbursement, correction of a benefit calculation, reconsideration under a proper standard, explanation, payment, or a more general complaint remedy. In the applicable federal external review process, the ACA external review provisions require prompt implementation of a decision reversing denial. Where clinical care is delayed, however, a later reimbursement decision cannot necessarily restore the lost opportunity to obtain treatment at the clinically appropriate time.
A complete scientific outcome record therefore separates the legal disposition from the performance of the remedy. Was a denial overturned? Was the authorization actually issued? Was treatment obtained? Did the provider receive payment? Was the claimant left with liability or additional financing costs? A favorable legal outcome and successful realization of care are related but independently observable events.
Timeliness, Fairness, and Empirical Outcomes
The denominator problem in administrative reports
The central empirical distinction in this field concerns the selection of cases. A claim-level denial rate is not a population-level probability of having medically necessary care denied. One person may have numerous small claims; another may have a single expensive episode. Some denials concern claims processing rather than clinical eligibility. An appeal database is smaller and selected by knowledge, ability, provider assistance, expected success, and the clinical importance of the disputed service.
The CMS Transparency in Coverage files provide issuer- and plan-level reporting for specified qualified health plan cohorts. Their data vintages follow the year of the claims as well as the year of the plans offered, and not all state-based marketplaces or employment coverage arrangements are included. KFF's analysis of 2024 marketplace claims reports around 451 million in-network claims and 85 million final in-network denials for the studied HealthCare.gov issuer population, an approximately 19 percent denial rate. Out-of-network claims had a higher reported rate of around 37 percent. These are transaction-level figures for the defined reporting group, not estimates for the whole U.S. health insurance sector.
Observed appeal and reversal frequencies
For the same KFF-reviewed 2024 dataset, fewer than 1 percent of reported in-network denials were formally internally appealed; at least 262,982 internal appeals were recorded against around 85 million denials. KFF reports approximately 66 percent of adjudicated internal appeals upheld the original denial. It also identifies at least 5,881 external appeals among reporting issuers and cautions that suppression of observations below ten prevents a reliable estimate of the external-review uphold rate. These are published 2024 appeals findings, and the percentages should not be combined as if each arose from one identical completely observed appeal cohort.
The small formal appeal fraction can arise through multiple mechanisms: administrative corrections may occur outside appeals; patients may accept an exclusion; a provider may handle the challenge; the contested amount may be small; the patient may not know the right exists; or the cost and urgency of pursuing review may deter action. It is therefore an inferential error to interpret non-appeal as assent to a denial's correctness. It is equally erroneous to interpret every denied claim as unlawful or clinically unjustified.
Independent review and the selection of difficult cases
Lin, Coffman, Douglas, and Phillips (2026) analyzed independently reviewed cases in four U.S. states in 2019–2023. Their independent medical review study found that nearly one-half of the selected coverage denials taken to independent medical review were overturned; the study also reports variation for cancer genetic testing. These findings concern a highly selected group that reached independent review. They demonstrate that substantive disagreement persists even after initial decisions and that the reviewed case mix matters, but they cannot be projected as a national reversal rate across all denied claims.
A voluntary external system may yield a higher reversal percentage because only unusually contested or professionally supported cases proceed. An automatic referral program may capture a different mix. A change in eligibility criteria may shift observed case composition without changing reviewer accuracy. When comparing programs, a researcher must therefore identify the path into the sample before drawing any quality conclusions from the outcomes.
Administrative burden and unequal access to appeals
Yaver (2024), in Rationing by Inconvenience, used a survey of 1,340 U.S. adults and 110 interviews with patients, clinicians, and former insurance executives. The published analysis connects denial appeals to learning, compliance, and psychological costs and reports that less affluent respondents were less likely to appeal. Horný, Yu, and Hoagland (2025), in Claim Denials and Administrative Burden, examine disparities in the burdens arising from denied claims. These studies are evidence of unequal experience and access within their designs, rather than a universal causal measurement for all countries.
An appeal right has practical value only when a claimant can recognize the denial, obtain the evidence, communicate in an accessible format, meet deadlines, and continue the process during illness or financial insecurity. The resources required to contest a decision can be thought of as a secondary cost of claiming the original insured benefit. For a household with low income, poor health, limited digital access, or insufficient language support, that cost may be decisive. Provider assistance, navigators, ombudsman services, and clear adverse notices can reduce barriers, though the magnitude of their effects must be measured rather than assumed.
Survey evidence and perceived entitlements
The KFF consumer experience survey interviewed 3,605 insured adults in the United States in 2023 and reported that a substantial majority experienced some insurance-use problems over the preceding year. Among those who encountered a problem, only about one in ten reported filing a formal appeal. The same research documents considerable uncertainty about external review rights and available consumer-assistance agencies. The KFF denied-claims survey analysis distinguishes a person reporting a denial of care expected to be covered from a claims dataset that includes multiple transactions per person.
Survey responses carry recall, interpretation, nonresponse, and timing limitations. An individual may use the phrase “claim denial” for a rejected prior authorization, a service that was later paid, or a contested bill. The value of the survey is its ability to measure knowledge, burden, and experiences that administrative files omit. Its estimates should be presented with survey populations and item definitions, and never directly pooled with transactional denial counts.
Timeliness as a clinically conditioned metric
Time to review is not merely a regulatory clock. It can be measured from adverse notice to appeal submission, from appeal receipt to internal decision, from final internal denial to external request, and from external decision to care or payment. Each interval has a different decision maker and potentially different accountability. The federal health-benefits appeals guidance and Medicaid appeal timing regulation show that urgency categories and public-program rules generate different statutory maxima.
A meaningful timeliness dataset should capture median, 90th and 95th percentile elapsed times, missed legal deadlines, clinically urgent cases, interruptions in ongoing care, and the time from reversal to executed remedy. A very short median can coexist with an intolerable upper tail. Administrative closure should be distinguished from receipt of treatment or payment. A health outcome analysis would also need clinical severity at the time of denial and a comparison group; raw waiting times alone cannot quantify causally attributable harm.
Accuracy, consistency, and interreviewer reliability
A reviewer may uphold the original decision because the claimant has no entitlement, or because evidence remains insufficient; a reversal may follow new documentation or a correction in applying the same rule. These outcomes are substantively different. Accuracy can be studied through blinded audit against an explicitly specified benchmark, repeat review by independent experts, examination of decision explanations, and records of actual remedy execution. Interreviewer agreement can be expressed as observed concordance or chance-adjusted agreement, but a high agreement coefficient does not establish substantive correctness when reviewers share the same mistaken rule.
Fairness also involves similar cases being treated consistently. Risk adjustment is needed when comparing plan-level results because cases differ by clinical severity, services, population, benefit design, and provider billing. Disparities warrant scrutiny, but a raw group difference is not itself sufficient to identify discriminatory treatment; conversely, similar overall reversal proportions can conceal disparate filing barriers. Both participation and conditional adjudication must be evaluated.
Hypothetical calculation: screening and appeal selection
Consider an expressly hypothetical cohort of 20,000 finally adjudicated post-service claims with 3,800 final denials. Suppose 38 of the denied claims are formally appealed and 15 of those appeals result in reversals. Then the final-denial rate is 3,800/20,000 = 19 percent; the appeal filing rate is 38/3,800 = 1 percent; the conditional reversal rate is 15/38 = 39.47 percent; and the portion of originally denied claims reversed through this recorded formal appeal route is 15/3,800 = 0.395 percent.
This example is a demonstration of denominators, not an estimate from the CMS data or a projection of any actual insurer. If additional cases were corrected through informal resubmission, the formal-appeal route would omit them. If the 38 appealed cases were concentrated among high-value medical services, the reversal rate would tell us little about the number of patients helped or aggregate benefit expenditure without further fields. If a subgroup had much lower appeal participation, its adjudicated appeal success could appear favorable while its overall access to relief remained inferior.
Reading trend data without false certainty
A change in reported denial fractions can follow altered benefit design, coding edits, shifts between in-network and out-of-network services, new reporting issuers, and movement between federal and state-based exchanges. The KFF reporting-methodology discussion emphasizes gaps in returning-plan information and the exclusion of some issuers from comparisons. Researchers should preserve the original raw file, data dictionary, extraction date, normalization code, inclusion rules, and missing-value treatment. Without these, an apparent time trend risks being a composition artifact.
In comparative reporting, the first scientific obligation is to explain how a number was constructed. A well-specified denominator, stable case definition, and documented legal scope contribute more to inference than an unsupported claim that one regulator or country has a uniformly superior review process.
Data, Measurement, Validation, and Regulatory Applicability
An auditable event-level record
A research-grade case history should include a privacy-preserving episode identifier, plan and scheme, benefit year, covered population, decision type, service stage, denial code and explanatory text, policy clause or statutory criterion, provider submission, relevant dates, urgency class, internal reconsideration, independent review, outcome, implementation, and eventual payment or service receipt. Person identifiers and health records require an appropriate legal basis, access controls, minimization, and secure handling. Sensitive clinical narratives should not be reproduced merely because they explain a denial.
Different event timestamps answer different questions. Receipt of a complete filing differs from first contact; notice mailing differs from notice receipt; service authorization differs from actual service; payment authorization differs from funds transferred. An interrupted or withdrawn appeal should be coded distinctly from a decided appeal. Denial reason codes should be versioned because categories change with billing systems and regulations. Reporting must preserve distinctions between patient-initiated and provider-initiated contestation and between formal appeal and correction of a technical submission.
Indicator definitions and interpretation
A defensible dashboard begins with claims finally adjudicated, denials, appeals initiated, appeals resolved, unresolved appeals by age, upheld decisions, reversals, partial reversals, cases not accepted for review, and successful execution of decisions. Additional indicators concern cost exposure, urgency, representation, accessibility, and delays by stage. The conventional fractions D/N, A/D, and R/A should be accompanied by exact counts and eligibility rules. Exclusions and missing counts must be described. Weighted averages across plans should not be confused with an unweighted average of plan-level rates.
The outcome measure for a clinical appeal can be defined in several ways: reversal within a legal deadline, authorization obtained, treatment completed, out-of-pocket burden reduced, or clinically appropriate care delivered. These outcomes are connected by an event sequence, but each requires a distinct observable measure. A regulator interested in timeliness may prioritize deadline compliance; a patient-safety researcher may prioritize clinical consequences; a financial analyst may prioritize payer and household transfers.
Missingness, suppression, and selection
Administrative claims data may suppress small cell counts, exclude withdrawn appeals, record only returning plans, or have inconsistent denial categories. The CMS public-use-file documentation identifies multiple file types and scope constraints. The KFF 2024 methodological notes explain that small external appeal cells may be suppressed and that the insurer and plan populations vary across reporting years. A suppressed value should be carried as censored or missing within its documented bound rather than uncritically replaced by zero when estimating population parameters.
Appeal cases are a selected subset of denied claims. In causal terms, filing A can be affected by severity, denial justification, income, language, knowledge, clinician support, and expected success. Conditioning only on A=1 can create selection distortions because the same variables can affect both the probability of appeal and the decision outcome. A measured reversal difference between two population groups should therefore be reported alongside their appeal initiation rates and material differences in cases.
Evaluation and identification strategies
One possible research design is a blinded random file audit, stratified by denial reason, medical urgency, insurance product, and jurisdiction. The audit can compare original adjudication with the legal and clinical benchmark in effect at the time. This estimates an adjudication error fraction within a defined target population if sampling and benchmark validity are preserved. An observational study of a new appeals portal or navigator service could use interrupted time series or a staggered difference-in-differences framework, but that design would require documented intervention timing, a justified comparison group, stable measurement, and assessment of parallel trends and spillovers.
An experiment that randomizes information or administrative assistance to eligible claimants could identify effects on appeals, successful corrections, and time to care subject to ethics and program rules. Even then, increased appeals could represent improved access rather than an increase in wrongful denials. Review metrics must be chosen before the intervention and interpreted in context; otherwise an organization could appear to deteriorate simply because more patients exercise legitimate rights.
Sensitivity analysis and robustness
Sensitivity tests should change the treatment of unknown outcomes, the inclusion of repeat submissions, the handling of missing urgency, the time origin for appeal deadlines, and the definition of a completed claim. For group comparisons, report standardized measures using a common case mix as well as raw estimates. For longitudinal analysis, hold insurer participation and plan definitions fixed where possible. When sample sizes are small, report appropriate confidence intervals; a rate of one reversal among two external appeals conveys far less statistical precision than a rate based on thousands of adjudications.
Because regulations change, each legal coding entry should carry a jurisdiction, instrument name, section, effective date, and retrieval date. The CMS July 2026 appeals update demonstrates why a current explanation may not accurately characterize cases processed under an earlier version. Anonymized decision letters should be retained only in lawful research environments; where public access is absent, the evidence ledger must distinguish verified official guidance from unaudited case-level assumptions.
Data ethics, explainability, and automation
Automated claims systems can assist with code validation, routing, record completeness checks, and flags for manual review. They can also propagate wrong coverage rules, produce opaque explanations, or incorrectly classify clinically significant cases. Scientific evaluation should preserve the version of the model or rules engine, input data quality, override decisions, manual reviewer expertise, and appeal outcomes. A technically precise denial code has little public value if a claimant cannot understand the reason or obtain the underlying standard.
Fairness auditing should jointly examine errors in denial, disparate opportunities to appeal, consistency of reason-giving, and remedy completion. Data minimization is necessary because revealing more clinical records to additional reviewers can itself create privacy costs. The goal is a traceable decision pathway that protects necessary patient information while allowing qualified parties to test the underlying reason for denial.
Boundary conditions of this evidence review
The present work evaluates official regulations and guidance in selected jurisdictions, an institutional data series, an inspector general evaluation, consumer surveys, and identified peer-reviewed studies. It does not reproduce or independently reanalyze the complete 2024 CMS microfiles. The PubMed records for the three peer-reviewed studies support the documented bibliographic identity and reported abstracts; the full journal articles are not represented as completely read. National enforcement practices, detailed state variations, and private plan terms remain separate evidence questions. These limits are substantive boundaries of the conclusions, not grounds to convert a descriptive synthesis into a new theory.
International Synthesis and Scientific Conclusions
Institutional comparison across five settings
The United States comprises multiple coexisting review architectures. ACA external medical review emphasizes independent review of eligible clinical and rescission issues under state or federal procedures. Employer-plan internal appeal obligations involve ERISA procedural rules where applicable. Medicare Advantage includes automatic independent reconsideration after certain adverse plan decisions. Medicaid managed care combines plan appeal with state fair hearing and, where offered, optional external medical review. The ACA external review framework, Medicare Part C IRE process, and Medicaid fair-hearing procedures show why treating U.S. health insurance review as a single national appeals queue would be methodologically false.
In the United Kingdom, private medical insurance complaints can proceed to the Financial Ombudsman Service, which weighs contract, law, and fairness within its remit. In Australia, the Commonwealth Ombudsman provides independent complaint support for private health cover. The Netherlands adds an institutional distinction between free mediation and a binding disputes board. European supervisory guidelines provide a common internal complaint-handling reference while national authorities determine the specific remedies. These choices illustrate alternative combinations of clinical expertise, ombudsman scrutiny, compulsory procedures, and binding adjudication.
An analytical account of effective review
The evidence supports an integrated reading of three outcomes. The first is the correctness of the original denial under the applicable legal and benefit standard. The second is the effective accessibility and impartiality of a procedure that can correct an adverse decision. The third is the realized effect of the remedy on payment, clinical service, or patient financial burden. They should be measured separately and analyzed together. This is an interpretive organization of established evidence, not a newly proposed doctrinal or theoretical system.
A legal entitlement can be recognized in a written notice while remaining impractical because the claimant cannot obtain documentation or meet procedural deadlines. An independent review can be procedurally impartial while constrained to a limited clinical question. A reversal can be correctly decided but implemented after a clinical opportunity has passed. The institutional success of an appeals system therefore depends on the relation among adjudicatory quality, access to the mechanism, and execution of outcomes.
Why reversal rates require cautious interpretation
A low overturn rate can arise where initial decisions are accurate, where poorly informed claimants appeal weak cases, or where barriers prevent strong cases from reaching review. A high overturn rate can reveal systematic initial error, effective correction of genuinely difficult cases, or highly selective filing. Administrative records alone rarely distinguish these mechanisms. The contrast between the very low formal internal-appeal participation reported by KFF's 2024 claims analysis and the substantial reversal fraction among selected independent reviews in Lin and colleagues' study is therefore informative about different pathways, not an estimate of all erroneous insurance denials.
The strongest empirical conclusion is a methodological one: to evaluate fairness, a researcher needs denominators for the entire eligible population, records of unappealed denials, the probability of entry into each review stage, and independent benchmarks for decision correctness. In the absence of such data, reversal and filing rates remain useful descriptive indicators with clearly bounded interpretation.
Governance implications drawn from existing evidence
Regulators and insurers can improve the measurability of review performance by adopting clear denial explanations, permitting access to claim files, recording review-stage timestamps, establishing reviewer independence, and tracking whether remedies were implemented. Health insurance consumer assistance may reduce learning and procedural costs, an issue illuminated by Yaver's administrative burden evidence and KFF's consumer survey. Each specific intervention remains an empirical proposition to be evaluated in its jurisdiction rather than a universally proven policy effect.
Comparative data collection would benefit from separating pre-service denials, post-service payment denials, coverage rescissions, and complaint categories. Review outcomes should be linked to service or payment consequences where ethical and legal conditions permit. A jurisdiction with strong procedural protections still requires evidence that patients can practically use them. Conversely, informal resolution practices should be measured because they can correct errors invisible to formal appeal reports.
Remaining research priorities
Further research should study whether the same denial would be reached by independently selected qualified reviewers under an identical benchmark; how clinical urgency interacts with review delays; whether representatives and navigators change appeal participation among less-resourced groups; how administrative resubmission differs from legal appeal; and what share of favorable rulings is realized as care or payment. International data harmonization should record legal scope rather than flattening diverse adjudicatory processes into one variable.
The historical and contemporary evidence establishes the central scientific conclusion of this dossier: claims appeals and independent review are essential mechanisms for testing the operational credibility of health insurance entitlements. Their performance is observable through justified decisions, fair participation, timely and independent reconsideration, and effective remedies. Reliable science begins by preserving the distinctions among these observable components.
Conclusion
The medical claim appeal is a mechanism by which a contested entitlement is examined after an insurer or public program has made an adverse benefit determination. A reliable claims system must connect the legal coverage obligation, the standard used in adjudication, timely and intelligible explanation, access to evidence, competent reconsideration, and execution of the final remedy. The regulatory comparison reveals genuinely different legal routes: internal and external review under ACA-derived federal requirements; a distinct employer-plan appeals regime; automatic independent reconsideration in Medicare Advantage; Medicaid plan appeals and state fair hearings; financial ombudsman review in the United Kingdom; supervisory complaint governance in Europe; and specialized dispute-resolution institutions in Australia and the Netherlands.
The empirical synthesis demonstrates that raw denial, appeal, and reversal percentages cannot substitute for evaluation of decision accuracy. The different denominators and selection processes identified in the CMS transparency datasets, 2024 marketplace analysis, independent review research, and administrative burden study establish why both unappealed denials and the costs of contestation deserve scientific attention. Independent review can overturn erroneous or disputable decisions, while actual improvement in access to care requires implementation before the opportunity to treat is lost.
The original analytical contribution of the dossier is an evidence-grounded comparative synthesis linking denial grounds, institutional jurisdiction, review access, timing, selection bias, and remedy completion. It supports measurement across the entire appeal pathway and more precise identification of unjustified or inaccessible denials. These are conclusions derived from the reviewed sources and research logic; they establish no newly authored theory, doctrine, or proprietary model. Further comparative case-file research and prospective evaluation of assistance measures remain necessary for causal estimates of the effects of review design on clinical access and financial protection.
References
U.S. Department of Health and Human Services and implementing agencies. (2026 access). 45 CFR § 147.136, Internal claims and appeals and external review processes. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-B/part-147/section-147.136
U.S. Department of Labor, Employee Benefits Security Administration. (2026 access). Filing a Claim for Your Health Benefits. https://www.dol.gov/agencies/ebsa/about-ebsa/our-activities/resource-center/publications/filing-a-claim-for-your-health-benefits
HealthCare.gov. (2026 access). Internal Appeals. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
HealthCare.gov. (2026 access). External Review. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
Centers for Medicare & Medicaid Services. (2026 access). HHS-Administered Federal External Review Process for Health Insurance Coverage. https://www.cms.gov/cciio/programs-and-initiatives/consumer-support-and-information/csg-ext-appeals-facts
Centers for Medicare & Medicaid Services. (2026). Reconsideration by the Medicare Advantage (Part C) Health Plan. https://www.cms.gov/medicare/appeals-grievances/managed-care/reconsideration-advantage-health-plan-part-c
Centers for Medicare & Medicaid Services. (2026). Reconsideration by Part C Independent Review Entity. https://www.cms.gov/medicare/appeals-grievances/managed-care/review-part-c-independent-entitiy
Centers for Medicare & Medicaid Services. (2026). Medicare Managed Care Appeals and Grievances. https://www.cms.gov/Medicare/appeals-grievances/managed-care
United States, Code of Federal Regulations. (2026 access). 42 CFR § 438.402, General requirements. https://www.law.cornell.edu/cfr/text/42/438.402
United States, Code of Federal Regulations. (2026 access). 42 CFR § 438.408, Resolution and notification: Grievances and appeals. https://www.law.cornell.edu/cfr/text/42/438.408
Centers for Medicare & Medicaid Services. (2026). Health Insurance Exchange Public Use Files. https://www.cms.gov/marketplace/resources/data/public-use-files
KFF. (2026). Claims Denials and Appeals in ACA Marketplace Plans in 2024. https://www.kff.org/patient-consumer-protections/claims-denials-and-appeals-in-aca-marketplace-plans-in-2024/
U.S. Department of Health and Human Services, Office of Inspector General. (2022). Some Medicare Advantage Organization Denials of Prior Authorization Requests Raise Concerns About Beneficiary Access to Medically Necessary Care. https://oig.hhs.gov/reports/all/2022/some-medicare-advantage-organization-denials-of-prior-authorization-requests-raise-concerns-about-beneficiary-access-to-medically-necessary-care/
KFF / Pollitz, K., Pestaina, K., Montero, A., Lopes, L., Valdes, I., Kirzinger, A. and Brodie, M.. (2023). KFF Survey of Consumer Experiences with Health Insurance. https://www.kff.org/affordable-care-act/kff-survey-of-consumer-experiences-with-health-insurance/
International Association of Insurance Supervisors. (2026 access). Insurance Core Principles and ComFrame Online Tool, ICP 19. https://www.iais.org/icp-online-tool/
Financial Conduct Authority. (2026). Insurance: Conduct of Business Sourcebook, ICOBS 8. https://handbook.fca.org.uk/handbook/icobs8
Financial Ombudsman Service. (2026 access). Private Medical and Dental Insurance. https://www.financial-ombudsman.org.uk/consumers/complaints-can-help/insurance/medical-insurance/private-medical-insurance
Financial Ombudsman Service. (2026 access). Time Limits. https://www.financial-ombudsman.org.uk/consumers/complaints-can-help/expect/time-limits
European Insurance and Occupational Pensions Authority. (2012 / 2023-hosted materials). Guidelines on Complaints-Handling by Insurance Undertakings. https://www.eiopa.europa.eu/publications/guidelines-complaints-handling-insurance-undertakings_en
Commonwealth Ombudsman, Australia. (2026 access). Private Health Insurance Complaints. https://www.ombudsman.gov.au/complaints/private-health-insurance-complaints
Stichting Klachten en Geschillen Zorgverzekeringen (SKGZ). (2026 access). English Complaint: Mediation and Disputes Board. https://www.skgz.nl/english-complaint
Yaver, Miranda. (2024). Rationing by Inconvenience: How Insurance Denials Induce Administrative Burdens, Journal of Health Politics, Policy and Law 49(4):539–565, DOI 10.1215/03616878-11186111. https://pubmed.ncbi.nlm.nih.gov/38324347/
Horný, Michal; Yu, Olivia; Hoagland, Alex. (2025). Claim Denials: Low-Income Patients From Disadvantaged Racial And Ethnic Groups Experienced The Largest Burdens, Health Affairs 44(6):707–715, DOI 10.1377/hlthaff.2024.01277. https://pubmed.ncbi.nlm.nih.gov/40456042/
Lin, Grace A.; Coffman, Janet M.; Douglas, Michael P.; Phillips, Kathryn A.. (2026). Use Of Independent Medical Review: Almost One-Half Of Coverage Denials Overturned, Health Affairs 45(1):63–67, DOI 10.1377/hlthaff.2025.00716. https://pubmed.ncbi.nlm.nih.gov/41370722/
KFF / Pollitz, Karen; Pestaina, Kaye; Lopes, Lunna; Wallace, Rayna; Lo, Justin. (2023). Consumer Survey Highlights Problems with Denied Health Insurance Claims. https://www.kff.org/affordable-care-act/consumer-survey-highlights-problems-with-denied-health-insurance-claims/